文献速递前列腺癌

泌尿外科医生与肿瘤内科医生开具一线阿比特龙或恩扎卢胺治疗mCRPC的结局比较:基于人群的研究

A Population-based Study Comparing Outcomes for Patients With Metastatic Castrate Resistant Prostate Cancer Treated by Urologists or Medical Oncologists With First Line Abiraterone Acetate or Enzalutamide.
PubMed 文献 · Urology · 2021-02-13

该研究基于加拿大安大略省2012-2017年行政健康数据,纳入3405例≥66岁未接受化疗的mCRPC患者,比较泌尿外科医生与肿瘤内科医生开具一线阿比特龙或恩扎卢胺后的毒性及全因死亡率。结果显示,由肿瘤内科医生治疗的患者住院/急诊就诊风险、毒性相关就诊风险及死亡风险均高于泌尿外科医生治疗者。

要点

  • 肿瘤内科医生治疗者住院/急诊风险较高(HR1.16)。
  • 肿瘤内科医生治疗者毒性相关就诊风险较高(HR1.34)。
  • 肿瘤内科医生治疗者全因死亡风险较高(HR1.16)。

核心结论

  • 由泌尿外科医生开具一线阿比特龙或恩扎卢胺的mCRPC患者,总体住院/急诊就诊及治疗相关毒性就诊少于肿瘤内科医生治疗者。

研究设计与样本

  • 基于人群的回顾性队列研究,利用加拿大安大略省2012-2017年行政健康数据,纳入3405例≥66岁未接受化疗的mCRPC患者。

主要发现

  • 3405例患者中,2407例(70.7%)接受阿比特龙,998例(29.3%)接受恩扎卢胺。
  • 1786例(52.5%)患者发生急诊就诊或住院。
  • 与泌尿外科医生相比,肿瘤内科医生治疗者住院/急诊风险增加(HR1.16,95%CI 1.03-1.31;P=.02)。
  • 肿瘤内科医生治疗者毒性相关就诊风险增加(HR1.34,95%CI 1.08-1.69;P=.01)。
  • 肿瘤内科医生治疗者全因死亡风险增加(HR1.16,95%CI 1.02-1.33;P=.02)。

临床怎么用

  • 在解读不同科室医生开具一线口服系统治疗的结局差异时,需考虑患者疾病负荷等未测量混杂因素。

局限性

  • 除PSA调整和既往治疗外,关于患者疾病负荷的信息有限。
  • 差异可能源于肿瘤内科医生管理的患者前列腺癌疾病负荷更高,和/或不同专科间患者管理的其他未测量差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To compare toxicity and all-cause mortality for mCRPC patients receiving first line oral systemic therapy prescribed by medical oncologists and urologists. METHODS: Population-based retrospective cohort study of chemotherapy-naïve men aged ≥66 years treated for mCRPC with first-line abiraterone or enzalutamide based on administrative health data (Ontario, Canada, 2012-2017). Primary outcomes were hospitalizations/ER visits for any cause or treatment-related toxicity during first-line mCRPC treatment. Secondary outcome was all-cause mortality. We calculated hazard ratios (HRs) comparing outcomes for different medical specialties using multivariable Cox proportional hazards models. RESULTS: Among 3405 mCRPC patients, 2407 (70.7%) received abiraterone and 998 (29.3%) received enzalutamide. 1786 (52.5%) patients visited the ER or were hospitalized. Men treated by medical oncologists had an increased risk of hospitalization/ER visits (HR1.16, 95%CI 1.03-1.31; P = .02), toxicity-related visits (HR1.34, 95%CI 1.08-1.69; P = .01), and mortality (HR1.16, 95%CI 1.02-1.33; P = .02) compared to urologists. Limited information was available, beyond PSA adjustment and prior treatment, on patient disease burden. CONCLUSION: We observed fewer hospital visits overall and for treatment-related toxicity for mCRPC patients who were prescribed first line abiraterone or enzalutamide by urologists compared to medical oncologists. These differences may result from higher prostate cancer disease burden in patients managed by medical oncologists, and/or other unmeasured differences in patient management between specialties.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Woon DTS, Finelli A, Cheung DC, et al. A Population-based Study Comparing Outcomes for Patients With Metastatic Castrate Resistant Prostate Cancer Treated by Urologists or Medical Oncologists With First Line Abiraterone Acetate or Enzalutamide. Urology. 2021. PMID: 33592224. doi:10.1016/j.urology.2020.11.080

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。